FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2510155164> ?p ?o ?g. }

• W2510155164 endingPage "460" @default.
• W2510155164 startingPage "460" @default.
• W2510155164 abstract "Although cigarette smoking typically begins in adolescence, evidence for successful pharmacological smoking cessation interventions for this population is scarce. In adult smokers, varenicline is the most effective single pharmacotherapy. The aim of this study was to assess the efficacy and tolerability of varenicline for smoking cessation in adolescents.We did a randomised, placebo-controlled trial with adolescent smokers aged 12–19 years who were seeking treatment to quit at 57 outpatient centres (in the USA, Russia, South Korea, Taiwan, Canada, and Georgia). Participants were randomly assigned (1:1:1) to receive 12 weeks of high-dose varenicline (1 mg twice daily; 0·5 mg twice daily if bodyweight ≤55 kg), low-dose varenicline (0·5 mg twice daily; 0·5 mg once daily if bodyweight ≤55 kg), or placebo, then followed up for 40 additional weeks. At all visits, participants received brief, developmentally tailored smoking cessation counselling (<10 min per session) delivered by a trained counsellor. The primary efficacy outcome was continuous abstinence from weeks 9 to 12, measured via a Nicotine Use Inventory and confirmed by urine cotinine testing. The primary tolerability outcome was frequency of treatment-emergent adverse events, including neuropsychiatric adverse events, occurring after the first dose and within 30 days of the last dose of study medication. This trial is registered with ClinicalTrials.gov, NCT01312909.Between April 26, 2011, and Jan 18, 2018, 312 participants were enrolled and completed participation in the study: 109 in the high-dose varenicline group, 103 in the low-dose varenicline group, and 100 in the placebo group. The continuous abstinence rates from week 9 to 12 were 20% (22 of 109) in the high-dose varenicline group, 27% (28 of 103) in the low-dose varenicline group, and 18% (18 of 100) in the placebo group. Abstinence rates between high-dose varenicline and placebo groups (odds ratio [OR] 1·18 [95% CI 0·59–2·37]; p=0·63) and between low-dose varenicline and placebo groups (1·73 [0·88–3·39]; p=0·11) did not differ significantly. Treatment-emergent adverse events occurred in 65 (60%) of 108 participants in the high-dose group, 53 (53%) of 100 in the low-dose group, and 52 (53%) of 99 in the placebo group, and most were rated as mild. Neuropsychiatric treatment-emergent adverse events occurred in 18 (17%) of 108 participants in the high-dose group, 11 (11%) of 100 in the low-dose group, and 12 (12%) of 99 in the placebo group, and none was rated as severe.This trial did not show an advantage in abstinence with varenicline compared with placebo among adolescent smokers. The rates of treatment-emergent adverse events were similar to those in previous trials of adult smokers, raising no new tolerability signals. These findings do not support the use of varenicline as a first-line pharmacotherapy for smoking cessation in adolescents.Pfizer." @default.
• W2510155164 created "2016-09-16" @default.
• W2510155164 creator A5026696867 @default.
• W2510155164 creator A5089909560 @default.
• W2510155164 date "2011-05-01" @default.
• W2510155164 modified "2023-09-26" @default.
• W2510155164 title "Varenicline Increases Smokeless Tobacco Cessation" @default.
• W2510155164 cites W2048021420 @default.
• W2510155164 doi "https://doi.org/10.1016/s0027-9684(15)30345-x" @default.
• W2510155164 hasPublicationYear "2011" @default.
• W2510155164 type Work @default.
• W2510155164 sameAs 2510155164 @default.
• W2510155164 citedByCount "0" @default.
• W2510155164 crossrefType "journal-article" @default.
• W2510155164 hasAuthorship W2510155164A5026696867 @default.
• W2510155164 hasAuthorship W2510155164A5089909560 @default.
• W2510155164 hasConcept C118552586 @default.
• W2510155164 hasConcept C126322002 @default.
• W2510155164 hasConcept C142724271 @default.
• W2510155164 hasConcept C168563851 @default.
• W2510155164 hasConcept C1862650 @default.
• W2510155164 hasConcept C197934379 @default.
• W2510155164 hasConcept C204787440 @default.
• W2510155164 hasConcept C27081682 @default.
• W2510155164 hasConcept C2776319443 @default.
• W2510155164 hasConcept C2777053506 @default.
• W2510155164 hasConcept C2777843972 @default.
• W2510155164 hasConcept C2778375690 @default.
• W2510155164 hasConcept C2779547902 @default.
• W2510155164 hasConcept C2780687700 @default.
• W2510155164 hasConcept C2908647359 @default.
• W2510155164 hasConcept C535046627 @default.
• W2510155164 hasConcept C71924100 @default.
• W2510155164 hasConcept C99454951 @default.
• W2510155164 hasConceptScore W2510155164C118552586 @default.
• W2510155164 hasConceptScore W2510155164C126322002 @default.
• W2510155164 hasConceptScore W2510155164C142724271 @default.
• W2510155164 hasConceptScore W2510155164C168563851 @default.
• W2510155164 hasConceptScore W2510155164C1862650 @default.
• W2510155164 hasConceptScore W2510155164C197934379 @default.
• W2510155164 hasConceptScore W2510155164C204787440 @default.
• W2510155164 hasConceptScore W2510155164C27081682 @default.
• W2510155164 hasConceptScore W2510155164C2776319443 @default.
• W2510155164 hasConceptScore W2510155164C2777053506 @default.
• W2510155164 hasConceptScore W2510155164C2777843972 @default.
• W2510155164 hasConceptScore W2510155164C2778375690 @default.
• W2510155164 hasConceptScore W2510155164C2779547902 @default.
• W2510155164 hasConceptScore W2510155164C2780687700 @default.
• W2510155164 hasConceptScore W2510155164C2908647359 @default.
• W2510155164 hasConceptScore W2510155164C535046627 @default.
• W2510155164 hasConceptScore W2510155164C71924100 @default.
• W2510155164 hasConceptScore W2510155164C99454951 @default.
• W2510155164 hasIssue "5" @default.
• W2510155164 hasLocation W25101551641 @default.
• W2510155164 hasOpenAccess W2510155164 @default.
• W2510155164 hasPrimaryLocation W25101551641 @default.
• W2510155164 hasRelatedWork W118023225 @default.
• W2510155164 hasRelatedWork W1963571728 @default.
• W2510155164 hasRelatedWork W1975973593 @default.
• W2510155164 hasRelatedWork W1984116490 @default.
• W2510155164 hasRelatedWork W1985796466 @default.
• W2510155164 hasRelatedWork W2062623049 @default.
• W2510155164 hasRelatedWork W2394810266 @default.
• W2510155164 hasRelatedWork W2546825120 @default.
• W2510155164 hasRelatedWork W2803424709 @default.
• W2510155164 hasRelatedWork W2945408945 @default.
• W2510155164 hasVolume "103" @default.
• W2510155164 isParatext "false" @default.
• W2510155164 isRetracted "false" @default.
• W2510155164 magId "2510155164" @default.
• W2510155164 workType "article" @default.